Clinical Trials Logo

Clinical Trial Summary

The primary objective assess the clinical activity of combination doxorubicin-containing chemotherapy plus monoclonal antibody anti-CD20 (Rituximab) plus intrathecal prophylactic chemotherapy and loco-regional radiotherapy in primary localised testicular DLCL and to assess the toxicity of this therapeutic strategy


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00210379
Study type Interventional
Source International Extranodal Lymphoma Study Group (IELSG)
Contact
Status Completed
Phase Phase 2
Start date November 2000
Completion date March 2007

See also
  Status Clinical Trial Phase
Terminated NCT00523939 - DepoCyt for Active Lymphomatous or Leukemic Meningitis Phase 2
Completed NCT02679196 - The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma Phase 1
Completed NCT00210314 - Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma Phase 2
Not yet recruiting NCT02992834 - Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma Phase 4
Withdrawn NCT00210340 - A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis Phase 1